April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Long-term Outcome of Cavitary Retinoblastoma in 22 Patients
Author Affiliations & Notes
  • juan c. iturralde
    Oncology, Wills eye, Philadelphia, Pennsylvania
  • Emil A. Say
    Oncology, Wills eye, Philadelphia, Pennsylvania
  • Arman Mashayekhi
    Oncology, Wills eye, Philadelphia, Pennsylvania
  • Sara Lally
    Oncology, Wills eye, Philadelphia, Pennsylvania
  • Carol L. Shields
    Oncology, Wills eye, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  juan C. iturralde, None; Emil A. Say, None; Arman Mashayekhi, None; Sara Lally, None; Carol L. Shields, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1597. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      juan c. iturralde, Emil A. Say, Arman Mashayekhi, Sara Lally, Carol L. Shields; Long-term Outcome of Cavitary Retinoblastoma in 22 Patients. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1597.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the long-term ocular and systemic outcome of cavitary retinoblastoma.

Methods: : Retrospective non-comparative chart review

Results: : Twenty-three eyes of 22 patients were included in the study with a median age at presentation of 15 months (range: 3 - 52 months). Fifteen (68%) were male and 7 (32%) were female. Based on the International Classification of Retinoblastoma (ICRB), 11 were classified as group B (48%), 3 were group C (13%), 7 were group D (30%), and 2 were group E (9%). Initial median tumor thickness was 7.1 mm (range, 1.5 - 17.5 mm), while median tumor diameter was 14.5 mm (range: 6.5 - 24.0 mm). Treatment consisted of systemic chemotherapy in 13 patients (59%), enucleation in 3 (14%), intra-arterial chemotherapy in 4 (18%), and observation in 2 (9%). After a median follow-up of 86 months, 22 eyes achieved local tumor control, while one eye (4%) had tumor recurrence treated with enucleation. No patient developed systemic metastasis.

Conclusions: : Cavitary retinoblastoma appears to be associated with excellent local and systemic prognosis following chemoreduction or intra-arterial chemotherapy with a 4% risk of local tumor recurrence after a median follow-up of 86 months.

Keywords: retina • retinoblastoma • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×